TrialA Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Trial details
- Registry ID
- NCT04196101
- Phase
- Phase 2
ENTA
Enanta Pharmaceuticals, Inc
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceEffects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
Trial details
- Registry ID
- NCT04633187
- Phase
- Phase 2
A Study to Evaluate EDP 938 Regimens in Children With RSV
Trial details
- Registry ID
- NCT04816721
- Phase
- Phase 2
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
Trial details
- Registry ID
- NCT05568706
- Phase
- Phase 2
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Trial details
- Registry ID
- NCT05616728
- Phase
- Phase 2
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
Trial details
- Registry ID
- NCT06170242
- Phase
- Phase 2
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Trial details
- Registry ID
- NCT07482657
- Phase
- Phase 2
Latest recorded trial changes
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
NCT05568706 · Enanta Pharmaceuticals, Inc
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Time to resolution of RSV Lower Respiratory Tract Disease (LRTD) symptoms
+ After
Measure: Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms Measure: Time to Complete Resolution of LRTD Symptoms for the mITT Population Measure: Time to Complete Resolution of LRTD Symptoms for the HR3 Population
Actual enrollment increased by 1 participants
− Before
186 participants (actual)
+ After
187 participants (actual)
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
NCT07482657 · Enanta Pharmaceuticals, Inc
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting